On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
Patients with active PsA initiating guselkumab were significantly (approximately two times) more likely to remain persistent with on-label therapy through 24 months versus SC TNFi, overall and among biologic-naïve and biologic-experienced subgroups.
Authors
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Y M Wang
- Bruno Émond (ORCID: https://orcid.org/0000-0002-0060-765X)
- Kana Yokoji
- Jessica A. Walsh (ORCID: https://orcid.org/0000-0002-4563-0845)
- Timothy Fitzgerald (ORCID: https://orcid.org/0000-0003-3441-1708)
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Samuel Schwartzbein
- Soumya D. Chakravarty (ORCID: https://orcid.org/0000-0001-7957-838X)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Shikha Singla (ORCID: https://orcid.org/0000-0002-5540-8850)
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
- Dominic Pilon
- Elizabeth Adamson (ORCID: https://orcid.org/0009-0004-6564-0778)
Institutions
- Johnson & Johnson (United States) (US)
- University of Washington (US)
- Medical College of Wisconsin (US)
- University of Utah (US)
- Swedish Medical Center (US)
- Southwestern Medical Center (US)
- Exercise and Survivorship Education Cancer Foundation (US)
- Drexel University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1007/s40744-025-00804-3
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company